Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Clinical trial NCT02555657 · COMPLETED

Trial details

NCT number: NCT02555657
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Triple Negative Breast Cancer

Start date: 2015-10-13
Primary completion: 2019-04-11
Enrollment: 622

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.